ArticleBMC public health2025
Diabetes influences the link between lipid accumulation products and sarcopenia among US adults, as evidenced by NHANES data.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe rising rates of obesity and Sarcopenia have attracted considerable academic interest. The Lipid Accumulation Product (LAP) serves as an indicator of abdominal obesity and cardiovascular risk; however, its association with Sarcopenia remains unexplored. The present study explores the relationship between LAP and Sarcopenia, with a focus on the intermediary function of diabetes in this association.
methodsCross-sectional data from 10,065 adults, collected through NHANES from 1999 to 2018, were analyzed. Multivariate logistic regression models were used to determine the odds ratio (OR) between LAP and Sarcopenia, and mediation analysis assessed diabetes's mediating effect on LAP-related Sarcopenia.
resultsThis study included a cohort of 10,065 participants aged 20 years and older, among whom 1,153 were diagnosed with Sarcopenia. In a fully adjusted model, the LAP exhibited a positive association with the prevalence of Sarcopenia (OR = 2.57, 95% CI = 1.46-4.50, P < 0.001). When LAP was transformed from a continuous to a categorical variable, higher LAP levels were associated with an increased prevalence of Sarcopenia compared to the lowest LAP quartile (OR = 4.70, 95% CI = 1.81-12.16, P < 0.001). The application of restricted cubic spline analysis revealed a curvilinear relationship between LAP and Sarcopenia prevalence, with a significant inflection point at LAP = 4. Subgroup and sensitivity analyses confirmed the consistent association between LAP and Sarcopenia. Additionally, diabetes mellitus was identified as a partial mediator in this association, accounting for a mediation proportion of 31.1%.
conclusionThe study reveals a significant correlation between elevated levels of LAP and an increased prevalence of Sarcopenia, with diabetes identified as a mediating factor in this association. Further research is required to investigate the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.